AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013
Between 2010 and the first quarter of 2013, biopharma engaged in 70 deals involving neurodegenerative disease assets covering a wide variety of targets – possibly a consequence of uncertainty about the underlying pathophysiology. AstraZeneca was the top deal maker in the field even as it moved away from CNS as a core therapeutic area.
You may also be interested in...
Schizophrenia Dominates Psychiatric Drug Deal-Making Since 2008
Of 34 deals in the psychiatric disorder space since 2008, none have been mergers and acquisitions, but two-thirds of such transactions have involved licensing of compounds before regulatory approval. The major deals in the space have been a multi-compound collaboration between Otsuka and Lundbeck and the failed tie-up between AstraZeneca and Targacept.
When Opportunity Knocks: Eisai Turns To Business Development
Starting in 2006, Eisai embarked on a bold campaign to reorient the company around cancer – with an emphasis on externally sourced innovation – that put aggressive business development front and center. Now as Eisai prepares to launch what may be its most transformative in-licensed product, the weight-loss therapy Belviq, signs of trouble have appeared in its trophy cancer franchise.
Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation
AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.